Highest-materiality recent filing
Hongchang International changes fiscal year end from Dec 31 to March 31
Board approved change on May 12, 2025, effective immediately.
Dismissed WWC, P.C. as independent auditor; appointed Enrome LLP for FY ending Dec 31, 2025, effective Apr 24, 2025.
Hongchang International ceases shell company status, filing amendment clarifies
Filed Amendment No. 1 to 8-K dated Sep 7, 2023 to clarify cessation of shell company status.
Hongchang International CFO Wendy Li and Director Xingjia Gao resign; CEO takes CFO role
CFO Wendy Li resigned May 8, 2024, for personal reasons; no disagreement with operations, policies, or practices.
Hongchang International director resigns; appoints new board secretary
Stephan Truly Busch resigned as director effective March 27, 2024; resignation unrelated to any policy disagreements.
Hongchang International completes name change; OTC ticker now HCIL
Name changed from Heyu Biological Technology Corporation to Hongchang International Co., Ltd, effective November 28, 2023.
Hongchang International adopts amended bylaws effective Nov 23, 2023
Board approved and adopted amended and restated bylaws on Nov 23, 2023.
Heyu Biological Technology renamed to Hongchang International Co., Ltd effective Nov 17
Name change approved by board Oct 6, 2023 and controlling shareholder (68.1% ownership) on Nov 17, 2023.
Acquired all shares of Hongchang BVI for 415.6M new shares (80.1% of post-acquisition total).
Heyu Biological to acquire Hongchang BVI in reverse merger; 80.1% control to sellers
Issues 415,582,375 shares (80.1% of post-close total) to acquire Hongchang BVI, which owns Fujian food industrial park.
Heyu Biological Technology effects 1-for-10 reverse stock split
One-for-ten reverse stock split effective August 8, 2023. Share count reduced by ratio of 1:10.
Heyu Biological appoints Zengqiang Lin as independent director
Appointed Mr. Zengqiang Lin as independent director effective February 17, 2023.
Heyu Bio receives SEC non-compliance letter; faces potential registration revocation
Received SEC letter dated Dec 17, 2021 (received Dec 30) citing non-compliance with Section 13(a) reporting.
Heyu Biological appoints Bo Lyu as CFO effective Nov. 30, 2021
Mr. Bo Lyu appointed Chief Financial Officer effective November 30, 2021.
On April 24, 2025, Ms. Qingqing Wang, the Board Secretary of the Company, notified the Board that she was resigning from the Board Secretary, effective as of April 24, 2025.
On April 24, 2025, Mr. Ban Siong Ang, a director and the Chairman of the Board of the Company, notified the Board that he was resigning from Chairman of the Board due to personal reasons, effective as of April 24, 2025.
Effective as of April 24, 2025, Mr. Zengqiang Lin, Chief Executive Officer, Chief Financial Officer, President and a director of the Company, was appointed as the Chairman of the Board of the Company.
Effective May 8, 2024, Ms. Wendy Li resigned as the Chief Financial Officer of Hongchang International Co., Ltd (the “Company”), due to personal reasons.
Effective May 8, 2024, Mr. Xingjia Gao resigned as a Director from the Board of the Company, due to personal reasons.
Effective May 8, 2024, Mr. Zengqiang Lin was appointed as the Chief Financial Officer of the Company, in addition to his appointments as the Chief Executive Officer and Director of the Company.
Effective March 27, 2024, Ms. Qingqing Wang was appointed as a Board Secretary of the Company by the Board.
Effective March 27, 2024, Mr. Stephan Truly Busch resigned as a director of Hongchang International Co., Ltd (the “Company”).
On February 17, 2023, the board of directors of Heyu Biological Technology Corporation (the “Company”) announced the appointment of Mr. Zengqiang Lin as an independent director of the Company, effective immediately.
On November 30,2021, Mr. Bo Lyu was appointed by the board of directors of Heyu Biological Technology Corporation (the “Company”) as the Company’s Chief Financial Officer, effective immediately.
Max materiality 0.95 · Median 0.35 · Most common event other_material